Showing results (401-410 of 520) with videos related to

Sort By:
Pageof 52
Clinical Lung Cancer|May 29, 2012
Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08)Martin Früh, Richard Cathomas, Marco Siano, et al.
Science Signaling|September 19, 2019
Tumor-derived TGF-β inhibits mitochondrial respiration to suppress IFN-γ production by human CD4+ T cellsSarah Dimeloe, Patrick Gubser, Jordan Loeliger, et al.
Frontiers in Immunology|November 6, 2023
13C tracer analysis reveals the landscape of metabolic checkpoints in human CD8+ T cell differentiation and exhaustionAlexander Kirchmair, Niloofar Nemati, Giorgia Lamberti, et al.
Swiss Medical Weekly|July 19, 2006
Clinical significance of cyclooxygenase-2 (COX-2) in multiple myelomaA Trojan, M Tinguely, S Vallet, et al.
Cancer Immunology, Immunotherapy : CII|July 30, 2008
Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patientsAshley J Knights, Natko Nuber, Christopher W Thomson, et al.
Cellular & Molecular Immunology|March 6, 2024
Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2Ronja Wieboldt, Michael Sandholzer, Emanuele Carlini, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 21, 2005
Gamma-amino butyric acid type B receptors stimulate neutrophil chemotaxis during ischemia-reperfusionMadhavi J Rane, David Gozal, Waseem Butt, et al.
Blood|February 28, 2002
Adapted NOD/SCID model supports development of phenotypically and functionally mature T cells from human umbilical cord blood CD34(+) cellsTessa C C Kerre, Greet De Smet, Magda De Smedt, et al.
Cancer Immunology Research|April 16, 2025
Targeting cancer-associated glycosylation for adoptive T cell therapy of solid tumorsAndreas Zingg, Reto Ritschard, Helen Thut, et al.
Journal for Immunotherapy of Cancer|May 24, 2018
Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse eventsHeinz Läubli, Catharina Balmelli, Lukas Kaufmann, et al.
Pageof 52